checkAd

    DGAP-Adhoc  3123  0 Kommentare MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced


    MOLOGEN AG / Key word(s): Patent

    02.09.2015 21:13

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Ad-hoc notification according to § 15 WpHG

    MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with
    chemotherapy announced

    Berlin, September 2, 2015 - MOLOGEN AG announces that the United States
    Patent and Trademark Office (PTO) has declared that it will grant a patent
    (Notice of Allowance) for the combined use of the lead product,
    immunotherapy MGN1703, with a chemotherapeutic agent. MGN1703 is currently
    being tested in a phase III IMPALA pivotal study, both as a monotherapy and
    in combination with chemotherapy. The patent will be granted for the USA
    and would, in the event of market approval there, cover the dosing regimen
    for MGN1703 in combination with chemotherapy. In addition, the patent will
    last probably several years longer than the initial patent for MGN1703
    (substance patent) and would therefore permit a longer exclusive
    commercialization than the initial patent.

    Contact
    Claudia Nickolaus
    Head of Investor Relations & Corporate Communications
    Tel: +49 - 30 - 84 17 88 - 38
    Fax: +49 - 30 - 84 17 88 - 50
    investor@mologen.com

    Note about risk for future predictions
    Certain information in this report contains forward-looking statements or
    the corresponding statements with negation or versions deviating from this
    or comparable terminology. These are described as forward-looking
    statements. In addition, all of the information given here that refers to
    planned or future results of business areas, key financial figures,
    developments of the financial situation or other financial figures or
    statistical data, is to be understood as such forward-looking statements.
    The company points out to investors that they should not rely on these
    forward-looking statements as predictions about actual future events. The
    company is not obligated and refuses to accept any liability for the
    forward-looking statements and has no obligation to update such statements
    in order to accurately reflect the current situation.


    02.09.2015 The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: MOLOGEN AG
    Fabeckstraße 30
    14195 Berlin
    Germany
    Phone: 030 / 841788-0
    Fax: 030 / 841788-50
    E-mail: presse@mologen.com
    Internet: www.mologen.com
    ISIN: DE0006637200
    WKN: 663720
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
    Stuttgart

    End of Announcement DGAP News-Service

    ---------------------------------------------------------------------------



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc MOLOGEN AG: U.S. patent for lead product MGN1703 in combination with chemotherapy announced MOLOGEN AG / Key word(s): Patent 02.09.2015 21:13 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. …